Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service coronary intervention (PCI) cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (254 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 264 | 11,359 | 47% |
| 2020 | 226 | 9,283 | 49% |
| 2021 | 237 |
Angioplasty, stenting, atherectomy, intravascular imaging. Professional codes (what the surgeon bills): CPT 92920, 92928, 92933, 92937, 92941, 92943; the hospital bills MS-DRG 246, 247, 248, 249, 321, 322, 323, 324, 325, 318, 359, 360.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 13% of the cases CMS names in Pennsylvania; 137 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 245 | 13,378−4.1%/yr | −4.1%/yr | 5.9 | 0% | 13,900 in 2030+0.6%/yr |
| New Jersey | 172 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Structural heart (TAVR, TEER) | 158 | 2,820+2.5%/yr | +2.5%/yr | 1.70.9× | 0% | 3,580 in 2030+4%/yr |
Coronary intervention (PCI) in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
| 2024 |
| 8,394 |
| 58% |
| 2025 est. | ≈ 8,120 | – |
| 2026 est. | ≈ 8,230 | – |
| 9,930 |
| 51% |
| 2022 | 220 | 8,763 | 53% |
| 2023 | 226 | 8,837 | 56% |
| 2024 | 224 | 8,394 | 58% |
| 2025 from claims | – | 8,118 7,450–8,589 | 59% |
| 2026 forecast | – | 8,232 7,243–9,499 | 59% |
| 2027 forecast | – | 8,257 7,059–9,840 | 59% |
| 2028 forecast | – | 8,280 6,909–10,139 | 60% |
| 2029 forecast | – | 8,303 6,781–10,412 | 60% |
| 2030 forecast | – | 8,324 6,668–10,667 | 61% |
In 2025, 58% inpatient hospital, 42% hospital outpatient, 1% surgery center.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 6,009−4.6%/yr |
| −4.6%/yr |
| 4.9 |
| 0% |
| 7,900 in 2030+4.7%/yr |
| Massachusetts | 103 | 4,352−4.8%/yr | −4.8%/yr | 4.0 | 0% | 4,790 in 2030+1.6%/yr |
| Connecticut | 40 | 1,475−9.6%/yr | −9.6%/yr | 3.6 | 0% | 1,300 in 2030−2.1%/yr |
| New Hampshire | 25 | 1,180−3.6%/yr | −3.6%/yr | 4.5 | 0% | 1,640 in 2030+5.7%/yr |
| Rhode Island | 15 | 674−3.8%/yr | −3.8%/yr | 5.8 | 0% | 740 in 2030+1.6%/yr |
| Maine | 17 | 602−13%/yr | −13%/yr | 3.0 | 0% | 600 in 20300%/yr |
| Vermont | 8 | 437−6.6%/yr | −6.6%/yr | 3.4 | 0% | 790 in 2030+10%/yr |
| 2 |
| 838−4.5%/yr |
| −4.5%/yr |
| 0.61.1× |
| 0% |
| 950 in 2030+2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 52% of company spending on these surgeons in 2025, +11 pts on 2024.
In 2025, 11 companies reported engagement with Pennsylvania’s surgeons worth $815K in consulting, speaking, meals and travel tied to these products, about $3,639 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 38 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.